Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Tsunoda

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
Oncology Letters|August 10, 2023
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapyRyotaro Ohkuma, Yuki Fujimoto, Katsuaki Ieguchi, et al.
The Journal of Dermatology|March 29, 2025
Comparing immunopathogenesis of non-human immunodeficiency virus immune reconstitution inflammatory syndrome and immune-related adverse events: A prospective multicenter cohort studyHirohiko Sueki, Seiko Sugiyama, Yumi Aoyama, et al.
International Journal of Oncology|December 28, 2020
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
Oncology Reports|July 7, 2020
High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
Clinical Immunology (Orlando, Fla.)|April 14, 2016
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumorsMutsunori Murahashi, Yasuki Hijikata, Kazunari Yamada, et al.
BMC Cancer|April 12, 2025
A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancerKeisuke Baba, Nobumi Suzuki, Chiyo K Imamura, et al.
Medicine|June 11, 2021
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapyYuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, et al.
BMC Cancer|June 10, 2018
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patientsAnne-Laure Giraudet, Philippe Alexandre Cassier, Chicaco Iwao-Fukukawa, et al.
International Journal of Cancer|June 6, 2025
Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacyKohei Tajima, Masahiro Hosonuma, Eiji Funayama, et al.
Cancer Science|January 23, 2024
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefitMasahiro Hosonuma, Yuya Hirasawa, Atsuo Kuramasu, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
Oncology Letters|August 10, 2023
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapyRyotaro Ohkuma, Yuki Fujimoto, Katsuaki Ieguchi, et al.
The Journal of Dermatology|March 29, 2025
Comparing immunopathogenesis of non-human immunodeficiency virus immune reconstitution inflammatory syndrome and immune-related adverse events: A prospective multicenter cohort studyHirohiko Sueki, Seiko Sugiyama, Yumi Aoyama, et al.
International Journal of Oncology|December 28, 2020
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
Oncology Reports|July 7, 2020
High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancerRyotaro Ohkuma, Erica Yada, Shumpei Ishikawa, et al.
Clinical Immunology (Orlando, Fla.)|April 14, 2016
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumorsMutsunori Murahashi, Yasuki Hijikata, Kazunari Yamada, et al.
BMC Cancer|April 12, 2025
A phase I/II trial evaluating the safety of increased-dose S- 1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancerKeisuke Baba, Nobumi Suzuki, Chiyo K Imamura, et al.
Medicine|June 11, 2021
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapyYuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, et al.
BMC Cancer|June 10, 2018
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patientsAnne-Laure Giraudet, Philippe Alexandre Cassier, Chicaco Iwao-Fukukawa, et al.
International Journal of Cancer|June 6, 2025
Combination therapy with levofloxacin and the probiotic Clostridium butyricum MIYAIRI 588 enhances immune checkpoint inhibitor efficacyKohei Tajima, Masahiro Hosonuma, Eiji Funayama, et al.
Cancer Science|January 23, 2024
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefitMasahiro Hosonuma, Yuya Hirasawa, Atsuo Kuramasu, et al.
Pageof 13